The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRtw Biotech Regulatory News (RTW)

Share Price Information for Rtw Biotech (RTW)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.43
Bid: 1.43
Ask: 1.45
Change: 0.015 (1.05%)
Spread: 0.02 (1.399%)
Open: 1.43
High: 1.43
Low: 1.42
Prev. Close: 1.425
RTW Live PriceLast checked at -
RTW Venture is an Investment Trust

To achieve positive absolute performance and superior long-term capital appreciation, with a focus on forming, building, and supporting world-class life sciences, biopharmaceutical and medical technology companies.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Change of status for US federal tax - PTP to PFIC

28 Nov 2022 07:00

RNS Number : 6969H
RTW Venture Fund Limited
28 November 2022
 

LEI: 549300Q7EXQQH6KF7Z84

28 November 2022

RTW Venture Fund Limited

Change of status for US federal tax purposes from PTP to a corporation

RTW Venture Fund Limited (the "Company") announces that it will, with effect from 1 December 2022, change its status for U.S. federal tax purposes from a "publicly traded partnership" or "PTP" to a corporation. The Company believes that the change in status will cause it to be treated as a "passive foreign investment company" or a "PFIC." This change has been necessitated by recent changes to U.S. tax legislation due to come into effect from January 1, 2023. Under this new legislation, custodians holding shares in companies treated as publicly traded partnerships would incur new withholding tax obligations. A number of custodians effecting transactions in the Company's Ordinary Shares have informed the Company that, as a result of this new U.S. withholding tax obligation, they will no longer hold or deal with the Ordinary Shares if the Company continues to be treated as a publicly traded partnership for U.S. federal income tax purposes. This would have a material adverse impact on the Company's Shareholders and the functioning of the market in its shares and consequently the Board has decided to file documentation with the U.S. Internal Revenue Service to change the Company's tax status to a corporation for U.S. purposes.

Related to the making of the tax election, the Company will also be carrying out a reorganisation of the arrangements pursuant to which an affiliate of the Investment Manager is allocated its share of the investment performance generated by the Company. Pursuant to this, the Company has established a new wholly-owned subsidiary, RTW Venture Fund Operating Limited, to which it will transfer its right to the profits and losses attributable to the Company's portfolio of assets. This reorganisation will have no economic impact on Shareholders and is being effected solely for the purpose of ensuring that the share of the investment performance generated by the Company which is allocable to an affiliate of the Investment Manager receives the same treatment for U.S. federal tax purposes as would have been the case if no tax election by the Company had been compelled by the change in U.S. tax law.

The current articles of incorporation of the Company (the "Existing Articles") reflect the status of the Company prior to the tax election as a PTP. Accordingly, the tax election made by the Board is inconsistent with, and amounts to a technical breach of, the provisions of the Existing Articles. Consequently, a circular will be published by the Company shortly, pursuant to which Shareholders will be asked (a) to ratify the decision of the Board to make the tax election; and (b) to approve the adoption of new articles, which will be updated to reflect the U.S. federal tax status of the Company following completion of the tax election and the reorganisation.

The change in tax status is not expected to have any effect on non-U.S. Shareholders. For U.S. Shareholders, the Company anticipates that each holder of Ordinary Shares will recognize gain or loss as though the Company had sold all of its assets and the Company thereafter be taxed as a PFIC. For those Shareholders who wish to be taxed under the qualified electing fund ("QEF") regime, the Company will provide annual information with respect to its income and gains. The Company, however, in no way warrants the information provided to Shareholders in any year will be sufficient to enable them to make or maintain a QEF election with respect to their Ordinary Shares. As the PFIC rules are complex, all Shareholders are advised to consult with their own tax advisors.

This information is not intended to be all-inclusive or to render specific professional tax advice. Shareholders are urged to consult with their independent tax advisors to determine the tax consequences. The Company does not provide tax or legal advice.

 

For Further Information:

RTW Investments, LP

+44 (0) 77 1741 7711

Woody Stileman, Managing Director

Buchanan

+44 (0)20 7466 5107

Charles Ryland

Henry Wilson

George Beale

J.P. Morgan Cazenove

+44 (0)20 7742 4000

William Simmonds

Jérémie Birnbaum

James Bouverat (Sales)

BofA Securities

+44 (0) 20 7628 1000

Edward Peel

Kieran Millar

Elysium Fund Management Limited

+44 (0) 14 8181 0100

Joanna Duquemin Nicolle, Chief Executive Officer

Sadie Morrison, Managing Director

Morgan Stanley Fund Services USA LLC

+1 (914) 225 8885

 

 

About RTW Venture Fund Limited:

RTW Venture Fund Limited (LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.

RTW Venture Fund Limited is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the RTW website at www.rtwfunds.com for more information.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBRBBTMTJTBRT
Date   Source Headline
17th Apr 20237:00 amRNSMonthly Valuation Update
6th Apr 202312:00 pmRNSAppointment of Numis as Joint Broker
31st Mar 20235:20 pmRNSDirector/PDMR Shareholding
31st Mar 20237:00 amRNSAnnual Financial Report
30th Mar 20234:35 pmRNSPrice Monitoring Extension
29th Mar 202310:47 amRNSPortfolio Company Update: Strategic Financing
16th Mar 20234:00 pmRNSDirector Declaration
14th Mar 20237:00 amRNSMonthly Valuation Update
13th Mar 20233:20 pmRNSUpdate re Silicon Valley Bank exposure
1st Mar 20232:45 pmRNSNew Investment in Cargo Therapeutics
1st Mar 202310:00 amRNSNew Investment in Oricell Therapeutics
14th Feb 20237:00 amRNSMonthly Valuation Update
13th Feb 20234:51 pmRNSPortfolio Company Update
26th Jan 202311:32 amRNSQuotedData's Weekly News & Interview
25th Jan 20237:00 amRNSQuarterly Update
20th Jan 20234:29 pmRNSUpdate research from QuotedData
16th Jan 20237:00 amRNSNet Asset Value(s)
22nd Dec 20224:23 pmRNSDirector/PDMR Shareholding
19th Dec 202211:17 amRNSResult of General Meeting
14th Dec 20227:00 amRNSNet Asset Value(s)
13th Dec 202210:01 amRNSEdison issues flash on RTW Venture Fund (RTW)
8th Dec 20225:57 pmRNSMaterial Update from Portfolio Company
7th Dec 20221:00 pmRNSNew Investment in Apogee Therapeutics
1st Dec 20227:00 amRNSPublication of Circular & Convening of EGM
30th Nov 20222:00 pmRNSDirector/PDMR Shareholding
28th Nov 20227:00 amRNSChange of status for US federal tax - PTP to PFIC
14th Nov 20227:00 amRNSNet Asset Value(s)
4th Nov 20224:04 pmRNSDirector/PDMR Shareholding
1st Nov 20225:07 pmRNSDirector/PDMR Shareholding
25th Oct 20227:00 amRNSQuarterly Update
20th Oct 20227:00 amRNSEdison issues review on RTW Venture Fund (RTW)
14th Oct 20227:00 amRNSNet Asset Value(s)
22nd Sep 20227:00 amRNSDirector/PDMR Shareholding
16th Sep 20227:00 amRNSPortfolio Company Update: Third Harmonic Bio IPO
15th Sep 20227:30 amRNSNet Asset Value(s)
15th Sep 20227:00 amRNSHalf-year Report
17th Aug 202212:00 pmRNSNotice of Interim Report
12th Aug 20227:00 amRNSNet Asset Value(s)
26th Jul 20227:00 amRNSQuarterly Update
19th Jul 20227:55 amRNSAdditional Investment in Portfolio Company
15th Jul 20227:00 amRNSNet Asset Value(s)
6th Jul 20227:00 amRNSPortfolio Company Transaction Update
21st Jun 20225:33 pmRNSResult of AGM
13th Jun 20227:00 amRNSNet Asset Value(s)
17th May 20227:00 amRNSNotice of AGM
13th May 20227:00 amRNSNet Asset Value(s)
28th Apr 20227:00 amRNSQuarterly Update
14th Apr 20227:05 amRNSNew Investment
14th Apr 20227:00 amRNSNet Asset Value(s)
4th Apr 20224:23 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.